Trial Profile

Phase II Clinical Study to Evaluate the Efficacy and Safety of GB226 in Treatment of Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive Who Failed in Platinum-based Chemotherapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Geptanolimab (Primary)
Indications Cervical cancer
Focus Therapeutic Use
Sponsors Genor Biopharma

Most Recent Events

06 Jun 2023 Results (Part 2, n=123; As of July 28, 2022) assessing the efficacy and safety of geptanolimab in the treatment of patients with recurrent or metastatic cervical cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
02 Mar 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
02 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com